Antibody with an engineered Fc region as a therapeutic agent against dengue virus infection

Antiviral Research

Volumn 124, Issue , 2015, Pages 61-68

  Ramadhany, Ririn ^a   Hirai, Itaru ^b   Sasaki, Tadahiro ^a   Ono, Ken Ichiro ^c   Ramasoota, Pongrama ^d   Ikuta, Kazuyoshi ^a   Kurosu, Takeshi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c Medical & Biological Laboratories Co Ltd   (Japan)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antibody dependent enhancement; Dengue; Human monoclonal antibody; IgG subclass; Neutralization

Indexed keywords

DENGUE VIRUS RECOMBINANT HUMAN MONOCLONAL ANTIBODY; FC RECEPTOR; HUMAN MONOCLONAL ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; INTERFERON RECEPTOR; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RNA; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; VIRUS ENVELOPE PROTEIN;

AGMK CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT ENHANCEMENT; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ARTICLE; CELL SURVIVAL; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; GENE INACTIVATION; IN VITRO STUDY; INFECTION PREVENTION; K562 CELL LINE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; SECONDARY INFECTION; VERO CELL LINE; VIRUS LOAD; VIRUS NEUTRALIZATION; ANIMAL; CROSS REACTION; DRUG EFFECTS; GENETICS; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; K-562 CELL LINE; MUTATION; PROTEIN ENGINEERING; SEVERE DENGUE; VIROLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY-DEPENDENT ENHANCEMENT; CROSS REACTIONS; DENGUE; DENGUE VIRUS; HEK293 CELLS; HUMANS; IMMUNOGLOBULIN G; K562 CELLS; MICE; MUTATION; PROTEIN ENGINEERING; RECEPTORS, IGG; SEVERE DENGUE; VERO CELLS; VIRAL ENVELOPE PROTEINS;

EID: 84946907363     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2015.10.012     Document Type: Article

References (36)

1. J.N. Arnold, M.R. Wormald, R.B. Sim, P.M. Rudd, and R.A. Dwek The impact of glycosilation on the biological function and structure of human immunoglobulins Annu. Rev. Immunol. 25 2007 21 50
2. S.J. Balsitis, K.L. Williams, R. Lachica, D. Flores, J.L. Kyle, E. Mehlhop, S. Johnson, M.S. Diamond, P.R. Beatty, and E. Harris Lethal antibody enhancement of Dengue disease in mice is prevented by Fc modification PLoS Pathog. 6 2010 e1000790
3. K. Boonak, B.M. Slike, T.H. Burgess, R.M. Mason, S. Wu, P. Sun, K. Porter, I.F. Rudiman, D. Yuwono, P. Puthavathana, and M.A. Marovitch Role of dendritic cells in antibody-dependent enhancement of Dengue virus infection J. Virol. 82 2008 3939 3951
4. K. Boonnak, B.M. Slike, G.C. Donofrio, and M.A. Marovich Human FcγRII cytoplasmic domains differentially influence antibody-mediated dengue virus infection J. Immunol. 190 2013 5659 5665
5. D.S. Burke, A. Nisalak, D.E. Johnson, and R.M. Scott A prospective study of dengue infections in Bangkok Am. J. Trop. Med. Hyg. 38 1988 172 180
6. T. Chareonsirisuthigul, S. Kalayanarooj, and S. Ubol Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells J. Gen. Virol. 88 2007 365 375
7. H.B. Fleit, and C.D. Kobasiuk The human monocyte-like cell line THP-1 expresses FcγRI and FcγRII J. Leukoc. Biol. 49 1991 556 565
8. R.R. Graham, M. Juffrie, R. Tan, C.G. Hayes, I. Laksono, C. Ma'roef, Sutaryo Erlin, K.R. Porter, and S.B. Halstead A prospective seroepidemiologic study on dengue in children four to nine years of age in Yogyakarta, Indonesia I. studies in 1995-1996 Am. J. Trop. Med. Hyg. 61 1999 412 419
9. M. Guilliams, P. Bruhns, Y. Saeys, H. Hammad, and B.N. Lambrecht The function of Fcγ receptors in dendritic cells and macrophages Nat. Rev. Immunol. 14 2014 94 108
10. S. Ha, Y. Ou, J. Vlasak, Y. Li, S. Wang, K. Vo, Y. Du, A. Mach, Y. Fang, and N. Zhang Isolation and characterization of IgG1 with asymmetrical Fc glycosylation Glycobiology 21 2011 1087 1096
11. K.A. Hanley, and S.C. Weaver Frontiers in Dengue Virus Research 2010 Caister Academic Press 266
12. H. Hotta, S. Hotta, H. Takada, S. Kotani, S. Tanaka, and M. Ohki Enhancement of Dengue virus type 2 replication in mouse macrophage cultures by bacterial cell walls, peptidoglycans, and a polymer of peptidoglycan subunits Infect. Immun. 41 1983 462 469
13. N. Kobayashi, Y. Suzuki, T. Tsuge, K. Okumura, C. Ra, and Y. Tomino FcRn-mediated transcytosis of immunoglobulin G in human renal proximal tubular epithelial cells Am. J. Physiol. Ren. Physiol. 282 2002 358 365
14. U. Kontny, I. Kurane, and F.A. Ennis Interferon gamma augments Fcγreceptor-mediated dengue virus infection of human monocytic cells J. Virol. 62 1988 3928 3933
15. T. Kurosu, C. Khamlert, S. Phanthanawiboon, K. Ikuta, and S. Anantapreecha Highly efficient rescue of dengue virus using a co-culture system with mosquito/mammalian cells Biochem. Biophys. Res. Commun. 394 2010 398 404
16. R. Littaua, I. Kurane, and F.A. Ennis Human IgG Fc receptor II mediates antibody-dependent enhancement of dengue virus infection J. Immunol. 144 1990 3183 3186
17. A. Lux, X. Yu, C.N. Scanlan, and F. Nimmerjahn Impact of immune complex size and glycosylation on IgG binding to human FcγRs J. Immunol. 190 2013 4315 4323
18. J.B. Mady, I. Kurane, D.V. Erbe, M.W. Fanger, and F.A. Ennis Neuraminidase augments Fcγ receptor II-mediated antibody-dependent enhancement of dengue virus infection J. Gen. Virol. 74 1993 839 844
19. P. Masrinoul, M.D. Omokoko, S. Pambudi, K. Ikuta, and T. Kurosu Serotype-specific anti-dengue virus NS1 mouse antibodies cross-react with prM and are potentially involved in virus production Viral Immunol. 26 2013 250 258
20. M.L. Moi, C.K. Lim, T. Takasaki, and I. Kurane Involvement of the Fcγ receptor IIA cytoplasmic domain in antibody-dependent enhancement of dengue virus infection J. Gen. Virol. 91 2010 103 111
21. J.S. Porterfield Immunological enhancement and the pathogenesis of dengue haemorrhagic fever J. Hyg. Lond. 89 1982 355 364
22. J.V. Ravetch, and S. Bolland IgG fc receptors Annu. Rev. Immunol. 19 2001 275 290
23. W.W. Rodrigo, X. Jin, S.D. Blackley, R.C. Rose, and J.J. Schlesinger Differential enhancement of dengue virus immune complex infectivity mediated by signaling-competent and signaling-incompetent human FcγRIA (CD64) or FcγRIIA (CD32) J. Virol. 80 2006 128 138
24. S.R. Santhosh, M.M. Parida, P.K. Dash, A. Pateriya, B. Pattnaik, H.K. Pradhan, N.K. Tripathi, S. Ambuj, N. Gupta, P. Saxena, and P.V. Lakshmana Rao Development and evaluation of SYBR Green I-based one-step real-time RT-PCR assay for detection and quantitation of Japanese encephalitis virus J. Virol. Methods 143 2007 73 80
25. T. Sasaki, C. Setthapramote, T. Kurosu, M. Nishimura, A. Asai, M.D. Omokoko, C. Pipattanaboon, P. Pitaksajjakul, K. Limkittikkul, A. Subchareon, P. Chaichana, T. Okabayashi, I. Hirai, P. Leaungwutisong, R. Misaki, K. Fujiyama, K. Ono, Y. Okuno, P. Ramasoota, and K. Ikuta Dengue virus neutralization and antibody-dependent enhancement activities of human monoclonal antibodies derived from dengue patients at acute phase of secondary infection Antivir. Res. 98 2013 423 431
26. S.L. Sazinsky, R.G. Ott, N.W. Silver, B. Tidor, J.V. Ravetch, and K.D. Wittrup Aglycosilated immunoglobulin G1 variants productively engage activating Fc receptors Proc. Natl. Acad. Sci. 105 2008 20167 20172
27. C. Setthapramote, T. Sasaki, O. Puiprom, K. Limkittikul, P. Pitaksajjakul, C. Pipattanaboon, M. Sasayama, P. Leuangwutiwong, W. Phumratanaprapin, S. Chamnachanan, T. Kusolsuk, A. Jittmittraphap, A. Asai, J.F. Arias, I. Hirai, M. Kuhara, Y. Okuno, T. Kurosu, P. Ramasoota, and K. Ikuta Human monoclonal antibodies to neutralize all dengue virus serotypes using lymphocytes from patients at acute phase of the secondary infection Biochem. Biophys. Res. Commun. 423 2012 867 872
28. R.L. Shields, A.K. Namenuk, K. Hong, Y.G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, J.A. Fox, and L.G. Presta High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R J. Biol. Chem. 276 2001 6591 6604
29. S. Siberil, C.A. Dutertre, C. Boix, E. Bonnin, R. Menez, E. Stura, S. Jorieux, W.H. Fridman, and J.L. Teillaud Molecular aspects of human FcγR interactions with IgG: functional and therapeutics consequences Immunol. Lett. 106 2006 111 118
30. H.M. van der Schaar, J.C. Wilschut, and J.M. Smit Role of antibodies in controlling dengue virus infection Immunobiology 214 2009 613 629
31. D.W. Vaughn, S. Green, S. Kalayarooj, B.L. Innis, S. Nimmanitya, S. Suntayakorn, T.P. Endy, B. Raengsakulrach, A.L. Rotman, F.A. Ennis, and A. Nisalak Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity J. Infect. Dis. 181 2000 2 9
32. M.P.B.W. Wahala, and Aravinda de Silva Review: the human antibody response to dengue virus infection Viruses 3 2011 2374 2395
33. A.P. West Jr.; and P.J. Bjorkman Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor Biochemistry 2000 39 2000 9698 9708
34. J. Whitehorn, and C.P. Simmons The pathogenesis of dengue Vaccine 29 2011 7221-7210
35. A. Wright, and S.L. Morrison Effect of glycosylation on antibody function: implication for genetic engineering Trends Biotechnol. 15 1997 26 32
36. M. Yasugi, R. Kubota-Koketsu, A. Yamashita, N. Kawashita, A. Du, R. Misaki, M. Kuhara, N. Boonsathorn, K. Fujiyama, Y. Okuno, T. Nakaya, and K. Ikuta Human monoclonal antibodies broadly protective against influenza B virus PLoS Pathog. 9 2013 e1003150